Decreased serum levels of glial markers and their relation with clinical parameters in patients with schizophrenia

Decreased serum levels of glial markers and their relation with clinical parameters in patients with schizophrenia

INTRODUCTION: The neurodevelopmental hypothesis of schizophrenia suggests that alterations of glial fibrillary acidic protein (GFAP) and glial cell line-derived neurotrophic factor (GDNF) functions may play a role in the pathogenesis of schizophrenia. However, there is limited information about the...

Full description

Bibliographic Details
Main Authors:	İhsan Çetin, Ömer Faruk Demirel, Tarık Sağlam, Nazım Yıldız, Alaattin Duran
Format:	Article
Language:	English
Published:	ANP Publishing 2023-09-01
Series:	Klinik Psikiyatri Dergisi
Subjects:	schizophrenia neurodegeneration gfap gdnf glial markers panss scores
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=kpd&un=KPD-81557

Similar Items

Comparison of Classical and Clozapine Treatment on Schizophrenia Using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT Imaging
Published: (2005-05-01)

Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia
by: Agnieszka Markiewicz-Gospodarek, et al.
Published: (2022-06-01)

Prevalence of depression in persons with schizophrenia – A cross-sectional study from a tertiary psychiatric hospital
by: Reshma Susan Mathew, et al.
Published: (2023-06-01)

Suicidal tendencies in Schizophrenia patients
by: A. Pascariu, et al.
Published: (2022-06-01)

Population Pharmacodynamic Models of Risperidone on PANSS Total Scores and Prolactin Levels in Schizophrenia
by: Zhiwei Huang, et al.
Published: (2024-01-01)

The Prevalence of Depressive Symptoms in Schizophrenia: A Cross-sectional Study
by: Senthilkumaran Chidambaram, et al.
Published: (2023-12-01)

Symptom remission and functional outcome in an Egyptian sample of patients with schizophrenia
by: Reem El Ghamry, et al.
Published: (2021-12-01)

Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Somaye Arabzadeh, et al.
Published: (2018-02-01)

Association between cerebral dopamine neurotrophic factor (CDNF) 2 polymorphisms and schizophrenia susceptibility and symptoms in the Han Chinese population
by: Yongfeng Yang, et al.
Published: (2018-01-01)

Abnormalities of the Amygdala in schizophrenia: a real world study
by: Guangen Zheng, et al.
Published: (2023-08-01)

Overlapping of clinical symptoms between schizophrenia and bipolar disorder
by: A. Tahirovic, et al.
Published: (2022-06-01)

Violence, neurocognitive function and clinical correlates in patients with schizophrenia
by: Yun Yi, et al.
Published: (2023-01-01)

Amygdala signal abnormality and cognitive impairment in drug-naïve schizophrenia
by: Huagui Guo, et al.
Published: (2023-04-01)

Relation of IGF-I and IGFBP5 gene expression levels in Schizophrenia patients
by: Sevgi Karabulut Uzunçakmak, et al.
Published: (2020-05-01)

Dataset on negative symptoms factors in patients with schizophrenia
by: T.V. Lezheiko, et al.
Published: (2022-02-01)

A Potential Biomarker for Predicting Schizophrenia: Metallothionein-1
by: Seda Yılmaz, et al.
Published: (2023-02-01)

Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia
by: Anna Tkachev, et al.
Published: (2021-05-01)

Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients
by: Chen Lin, et al.
Published: (2021-11-01)

A case of glial fibrillary acidotic protein (GFAP) meningoencephalitis with rheumatoid arthritis
by: Mehri Salari, et al.
Published: (2023-03-01)

Clinical and cortical similarities identified between bipolar disorder I and schizophrenia: A multivariate approach
by: Kelly Rootes-Murdy, et al.
Published: (2022-11-01)

Symptomatic Profile of Cariprazine in the Context of ICD-11 Domains for Schizophrenia: Review of Clinically Oriented Studies
by: Alexey Viktorovich Pavlichenko, et al.
Published: (2022-01-01)

Parainfectious Anti-Glial Fibrillary Acidic Protein-Associated Meningoencephalitis
by: Jae Young Joo, et al.
Published: (2022-01-01)

Case report: Headache as the sole neurological symptom in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy
by: Eslam Shosha, et al.
Published: (2024-04-01)

C-Reactive Protein Correlates with Negative Symptoms in Patients with Schizophrenia
by: Ted Boozalis, et al.
Published: (2018-01-01)

Standardized training in the rating of the six-item positive and negative syndrome scale (PANSS-6)
by: P. Kølbæk, et al.
Published: (2021-04-01)

Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
by: Yi-Lung Chen, et al.
Published: (2018-12-01)

Autoimmune glial fibrillary acidic protein astrocytopathy associated with breast cancer: a case report
by: Tomonori Yaguchi, et al.
Published: (2023-04-01)

Effect of Vitamin D Supplementation on Cardiometabolic Indices and the Severity of Symptoms in Male Patients With Chronic Schizophrenia
by: Parinaz Kalejahi, et al.
Published: (2023-07-01)

A new sex-specific underlying mechanism for female schizophrenia: accelerated skewed X chromosome inactivation
by: Xinzhu Zhang, et al.
Published: (2020-07-01)

Discrepancy in the Usage of GFAP as a Marker of Satellite Glial Cell Reactivity
by: Kjeld Morten Mohr, et al.
Published: (2021-08-01)

Autistic Symptoms and Social Cognition Predict Real-World Outcomes in Patients With Schizophrenia
by: Giacomo Deste, et al.
Published: (2020-06-01)

Whether Serum Glial Fibrillary Acidic Protein (GFAP) Can Be Used as a Diagnostic Biomarker in Patients With Glioblastoma?
by: Charandeep Singh Gandhoke, et al.
Published: (2020-01-01)

Serum glial cell line-derived neurotrophic factor levels and impulsivity in heroin addiction: a cross-sectional, case-control study of 129 heroin addicts
by: Vahap Ozan Kotan, et al.
Published: (2018-04-01)

Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy in Children: A Retrospective Analysis of 35 Cases
by: Hongjun Fang, et al.
Published: (2021-11-01)

Evaluation of the Effect of Alkaloid Berberine on the Positive and Negative Symptoms of the Patients with Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial
by: Ebrahim Moghimi Sarani, et al.
Published: (2022-09-01)

Associations of Genetic Polymorphisms and Neuroimmune Markers With Some Parameters of Frontal Lobe Dysfunction in Schizophrenia
by: Anna Morozova, et al.
Published: (2021-05-01)

Suicide Attempts, Neurocognitive Dysfunctions and Clinical Correlates in Middle-Aged and Elderly Chinese Schizophrenia Patients
by: Yuanyuan Huang, et al.
Published: (2021-05-01)

Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances
by: Federica Pinna, et al.
Published: (2014-12-01)

Analysis of Acute and Chronic Methamphetamine Treatment in Mice on Gdnf System Expression Reveals a Potential Mechanism of Schizophrenia Susceptibility
by: Laoise Casserly, et al.
Published: (2023-09-01)

Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial
by: Paul H. Lysaker, et al.
Published: (2022-08-01)